- Home
- APVO vs CHNR Comparison
APVO vs CHNR Comparison
Compare APVO & CHNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- CHNR
- Stock Information
- Founded
- APVO 2016
- CHNR N/A
- Country
- APVO United States
- CHNR China
- Employees
- APVO N/A
- CHNR N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- CHNR Precious Metals
- Sector
- APVO Health Care
- CHNR Basic Materials
- Exchange
- APVO Nasdaq
- CHNR Nasdaq
- Market Cap
- APVO 4.1M
- CHNR 4.6M
- IPO Year
- APVO N/A
- CHNR 1995
- Fundamental
- Price
- APVO $3.23
- CHNR $3.92
- Analyst Decision
- APVO Strong Buy
- CHNR
- Analyst Count
- APVO 1
- CHNR 0
- Target Price
- APVO $5,920.00
- CHNR N/A
- AVG Volume (30 Days)
- APVO 6.7M
- CHNR 150.4K
- Earning Date
- APVO 08-07-2025
- CHNR 05-15-2025
- Dividend Yield
- APVO N/A
- CHNR N/A
- EPS Growth
- APVO N/A
- CHNR N/A
- EPS
- APVO N/A
- CHNR N/A
- Revenue
- APVO N/A
- CHNR N/A
- Revenue This Year
- APVO N/A
- CHNR N/A
- Revenue Next Year
- APVO N/A
- CHNR N/A
- P/E Ratio
- APVO N/A
- CHNR N/A
- Revenue Growth
- APVO N/A
- CHNR N/A
- 52 Week Low
- APVO $2.81
- CHNR $3.57
- 52 Week High
- APVO $485.37
- CHNR $9.04
- Technical
- Relative Strength Index (RSI)
- APVO 34.28
- CHNR 44.82
- Support Level
- APVO $2.81
- CHNR $3.66
- Resistance Level
- APVO $13.11
- CHNR $4.30
- Average True Range (ATR)
- APVO 1.10
- CHNR 0.68
- MACD
- APVO 0.30
- CHNR -0.04
- Stochastic Oscillator
- APVO 4.08
- CHNR 9.64
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.